BIRC5 and ovarian cancer: Using the CRISPR/Cas9 system, Zhao et al. showed that TGF-β could be attenuated by knockdown of BIRC5, the gene encoding Survivin, in ovarian cancer cells SKOV3 and OVCAR3 signaling that inhibits cancer cell proliferation and migration and restores sensitivity to paclitaxel (Zhao et al., 2017).